Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma

被引:112
作者
Doolittle, Nancy D. [1 ]
Korfel, Agnieszka [2 ]
Lubow, Meredith A. [1 ]
Schorb, Elisabeth [3 ]
Schlegel, Uwe [4 ]
Rogowski, Sabine [4 ]
Fu, Rongwei [1 ]
Dosa, Edit [5 ]
Illerhaus, Gerald [3 ]
Kraemer, Dale F. [6 ]
Muldoon, Leslie L. [1 ]
Calabrese, Pasquale [7 ]
Hedrick, Nancy [1 ]
Tyson, Rose Marie [1 ]
Jahnke, Kristoph [2 ]
Maron, Leeza M. [1 ]
Butler, Robert W. [1 ]
Neuwelt, Edward A. [1 ,8 ]
机构
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Freiburg, Med Ctr, Freiburg, Germany
[4] Univ Hosp Bochum, Knappschaftskrankenhaus, Bochum, Germany
[5] Semmelweis Univ, H-1085 Budapest, Hungary
[6] Univ Florida, Gainesville, FL 32611 USA
[7] Univ Basel, Basel, Switzerland
[8] Dept Vet Affairs Med Ctr, Portland, OR USA
关键词
METHOTREXATE-BASED THERAPY; WHOLE-BRAIN RADIOTHERAPY; HIGH-DOSE METHOTREXATE; NEUROCOGNITIVE FUNCTION; FOLLOW-UP; CLINICAL-TRIALS; CHEMOTHERAPY; SURVIVORS; OUTCOMES;
D O I
10.1212/WNL.0b013e318297eeba
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To describe and correlate neurotoxicity indicators in long-term primary CNS lymphoma (PCNSL) survivors who were treated with high-dose methotrexate-based regimens with or without whole-brain radiotherapy (WBRT). Methods: Eighty PCNSL survivors from 4 treatment groups (1 with WBRT and 3 without WBRT) who were a minimum of 2 years after diagnosis and in complete remission underwent prospective neuropsychological, quality-of-life (QOL), and brain MRI evaluation. Clinical characteristics were compared among treatments by using the chi(2) test and analysis of variance. The association among neuroimaging, neuropsychological, and QOL outcomes was assessed by using the Pearson correlation coefficient. Results: The median interval from diagnosis to evaluation was 5.5 years (minimum, 2 years; maximum, 26 years). Survivors treated with WBRT had lower mean scores in attention/executive function (p = 0.0011), motor skills (p = 0.0023), and neuropsychological composite score (p = 0.0051) compared with those treated without WBRT. Verbal memory was better in survivors with ;longer intervals from diagnosis to evaluation (p = 0.0045). On brain imaging, mean areas of total T2 abnormalities were different among treatments (p = 0.0006). Total T2 abnormalities after WBRT were more than twice the mean of any non-WBRT group and were associated with poorer neuropsychological and QOL outcomes. Conclusions: Our results suggest that in patients treated for PCNSL achieving complete remission and surviving at least 2 years, the addition of WBRT to methotrexate-based chemotherapy increases the risk of treatment-related neurotoxicity. Verbal memory may improve over time. Classification of evidence: This study provides Class III evidence that in patients treated for PCNSL achieving complete remission and surviving at least 2 years, the addition of WBRT to methotrexate-based chemotherapy increases the risk of treatment-related neurotoxicity.
引用
收藏
页码:84 / 92
页数:9
相关论文
共 35 条
[21]  
Heaton R. K., 2004, Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults, DOI [10.1051/matecconf/201710303003, DOI 10.1051/MATECCONF/201710303003]
[22]   Long-Term Survival with Favorable Cognitive Outcome after Chemotherapy in Primary Central Nervous System Lymphoma [J].
Juergens, Annika ;
Pels, Hendrik ;
Rogowski, Sabine ;
Fliessbach, Klaus ;
Glasmacher, Axel ;
Engert, Andreas ;
Reiser, Marcel ;
Diehl, Volker ;
Vogt-Schaden, Marlies ;
Egerer, Gerlinde ;
Schackert, Gabriele ;
Reichmann, Heinz ;
Kroschinsky, Frank ;
Bode, Udo ;
Herrlinger, Ulrich ;
Linnebank, Michael ;
Deckert, Martina ;
Fimmers, Rolf ;
Schmidt-Wolf, Ingo G. H. ;
Schlegel, Uwe .
ANNALS OF NEUROLOGY, 2010, 67 (02) :182-189
[23]   Treatment-induced leukoencephalopathy in primary CNS lymphoma - A clinical and autopsy study [J].
Lai, R ;
Abrey, LE ;
Rosenblum, MK ;
DeAngelis, LM .
NEUROLOGY, 2004, 62 (03) :451-456
[24]   Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma [J].
McAllister, LD ;
Doolittle, ND ;
Guastadisegni, PE ;
Kraemer, DF ;
Lacy, CA ;
Crossen, JR ;
Neuwelt, EA .
NEUROSURGERY, 2000, 46 (01) :51-60
[25]   Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors [J].
Meyers, CA ;
Brown, PD .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (08) :1305-1309
[26]   Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial [J].
Meyers, CA ;
Smith, JA ;
Bezjak, A ;
Mehta, MP ;
Liebmann, J ;
Illidge, T ;
Kunkler, I ;
Caudrelier, JM ;
Eisenberg, PD ;
Meerwaldt, J ;
Siemers, R ;
Carrie, C ;
Gaspar, LE ;
Curran, W ;
Phan, SC ;
Miller, RA ;
Renschler, MF .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :157-165
[27]   Therapeutic challenges in primary CNS lymphoma [J].
Morris, Patrick G. ;
Abrey, Lauren E. .
LANCET NEUROLOGY, 2009, 8 (06) :581-592
[28]  
Neuwelt EA, 2005, AM J NEURORADIOL, V26, P258
[29]   Development and psychometric properties of the Brief Test of Attention [J].
Schretlen, D ;
Bobholz, JH ;
Brandt, J .
CLINICAL NEUROPSYCHOLOGIST, 1996, 10 (01) :80-89
[30]   Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma [J].
Shah, Gaurav D. ;
Yahalom, Joachim ;
Correa, Denise D. ;
Lai, Rose K. ;
Raizer, Jeffrey J. ;
Schiff, David ;
LaRocca, Renato ;
Grant, Barbara ;
DeAngelis, Lisa M. ;
Abrey, Lauren E. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4730-4735